Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canadian company, which develops barium, iodine and carbon active pharmaceutical ingredients. The Company is focused on producing its own barium, iodine and fullerene minerals. The Company, through its subsidiaries, Voyageur Industrial Minerals Ltd. and Voyageur Minerals Inc., is engaged in acquiring, exploring and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada and the state of Utah, United States. Its properties include Jubilee Mountain, Falcon and Paradox Basin. It owns a 100% interest in two barium sulphate (barite) projects, including the Frances Creek and Pedley Mountain property. It holds interests in a high-grade iodine, lithium, and bromine brine project situated in Utah, United States. It owns a 100% interest in two battery mineral projects that is focused on copper/zinc development. Its pipeline products include SmoothX 2.0%, MultiX Thick, MultiX Thin, HDX, LDX, VY-101 and VY-103.


TSXV:VM - Post by User

Comment by postie1on Feb 22, 2021 8:54pm
131 Views
Post# 32633418

RE:RE:VM: Financing

RE:RE:VM: FinancingAgreed Billybub. Does this part of WOs valuation post not  look better than share dilution. PP only if necessary but if game plan works out there is cash flow to develop their sites. Cash flow also makes financing an option if needed..

" FDA Applications for barium contrast to be filed upon closing of financing. The FDA is working diligently with Voyageur to ensure USA barium contrast monopoly is broken. USA distribution companies project $5million in sales of barium products immediately, with room to grow quickly into a USA $60,000,000 barium contrast market. A proven marketing strategy to leverage our barium contrast to acquire 20 times more sales of iodine contrast. For every bottle of barium sold, 20 bottles of iodine may be sold to the same customer." 
<< Previous
Bullboard Posts
Next >>